Repatha Cuts Heart Attack Risk 20% in 544,000 Study
Repatha Cuts Heart Attack Risk 20% in 544,000 Study
Repatha Cuts Heart Attack Risk 20% in 544,000 Study
Key points
اہم نکات
मुख्य बातें
- A cholesterol injection cut the risk of heart attack by 20% compared with a daily pill in a study of more than 544,000 American heart patients, drugmaker Amgen announced on 5 November.
- Patients taking Repatha (evolocumab) had a 5.88% risk of a fatal or non-fatal heart attack over four years, against 7.76% for those taking ezetimibe (Zetia) — a gap of about 1.9 percentage points.
- The real-world study, published in the American Journal of Preventive Cardiology, covered adults with heart disease who had already used statins.
- A cholesterol injection cut the risk of heart attack by 20% compared with a daily pill in a study of more than 544,000 American heart patients, drugmaker Amgen announced on 5 November.
- Patients taking Repatha (evolocumab) had a 5.88% risk of a fatal or non-fatal heart attack over four years, against 7.76% for those taking ezetimibe (Zetia) — a gap of about 1.9 percentage points.
- The real-world study, published in the American Journal of Preventive Cardiology, covered adults with heart disease who had already used statins.
- A cholesterol injection cut the risk of heart attack by 20% compared with a daily pill in a study of more than 544,000 American heart patients, drugmaker Amgen announced on 5 November.
- Patients taking Repatha (evolocumab) had a 5.88% risk of a fatal or non-fatal heart attack over four years, against 7.76% for those taking ezetimibe (Zetia) — a gap of about 1.9 percentage points.
- The real-world study, published in the American Journal of Preventive Cardiology, covered adults with heart disease who had already used statins.
A cholesterol injection cut the risk of heart attack by 20% compared with a daily pill in a study of more than 544,000 American heart patients, drugmaker Amgen announced on 5 November. Patients taking Repatha (evolocumab) had a 5.88% risk of a fatal or non-fatal heart attack over four years, against 7.76% for those taking ezetimibe (Zetia) — a gap of about 1.9 percentage points. The real-world study, published in the American Journal of Preventive Cardiology, covered adults with heart disease who had already used statins. The study was observational and funded by Amgen, so it shows a link rather than proof, and a head-to-head randomised trial is still needed.
A cholesterol injection cut the risk of heart attack by 20% compared with a daily pill in a study of more than 544,000 American heart patients, drugmaker Amgen announced on 5 November. Patients taking Repatha (evolocumab) had a 5.88% risk of a fatal or non-fatal heart attack over four years, against 7.76% for those taking ezetimibe (Zetia) — a gap of about 1.9 percentage points. The real-world study, published in the American Journal of Preventive Cardiology, covered adults with heart disease who had already used statins. The study was observational and funded by Amgen, so it shows a link rather than proof, and a head-to-head randomised trial is still needed.
A cholesterol injection cut the risk of heart attack by 20% compared with a daily pill in a study of more than 544,000 American heart patients, drugmaker Amgen announced on 5 November. Patients taking Repatha (evolocumab) had a 5.88% risk of a fatal or non-fatal heart attack over four years, against 7.76% for those taking ezetimibe (Zetia) — a gap of about 1.9 percentage points. The real-world study, published in the American Journal of Preventive Cardiology, covered adults with heart disease who had already used statins. The study was observational and funded by Amgen, so it shows a link rather than proof, and a head-to-head randomised trial is still needed.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।